Archive January 4, 2018 Deciphera Pharmaceuticals Initiates Phase 3 Clinical Study with DCC-2618 in Patients with Advanced Gastrointestinal Stromal Tumors (“INVICTUS” study)
Archive January 3, 2018 Deciphera Pharmaceuticals, Inc. to Present at the 36th Annual J.P. Morgan Healthcare Conference
Archive November 28, 2017 Deciphera Pharmaceuticals, Inc. Announces Orphan Drug Designation from the EMA for DCC-2618 for the Treatment of Gastrointestinal Stromal Tumors
Archive November 21, 2017 Deciphera Pharmaceuticals, Inc. to Present at the 29th Annual Piper Jaffray Healthcare Conference
Archive November 20, 2017 Deciphera Pharmaceuticals Reports Data from Ongoing Phase 1 Clinical Study of DCC-2618 at the 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
Archive November 14, 2017 Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2017 Financial Results and Corporate Highlights
Archive November 10, 2017 Deciphera Pharmaceuticals, Inc. Reports Data Analysis from the Ongoing Phase 1 Clinical Trial of DCC-2618 at the Annual Meeting of The Connective Tissue Oncology Society
Archive November 6, 2017 Deciphera Pharmaceuticals, Inc. to Report Clinical Data with DCC-2618 at the Upcoming 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
Archive October 3, 2017 Deciphera Pharmaceuticals Announces Closing of Initial Public Offering and Exercise of Option to Purchase Additional Shares
